Table 1

Study cohort of HLA-A*02-positive cHBV patients with low viral load

Patient ID	Age (years)	Sex	VL (IU/mL)	HBsAg (IU/mL)	ALT (U/L)	Therapy	WT viral sequences	Detectable CD8+ T cell response
cHBV1	31	M	1863	5920.66	36	Naive	core₁₈, env₁₈₃	core₁₈
cHBV2	45	F	1965	3.96	27	Naive	core₁₈, pol₄₅₅	core₁₈, pol₄₅₅
cHBV3	42	F	889	925.22	15	Naive	core₁₈	core₁₈
cHBV4	52	F	2425	786.77	36	Naive	core₁₈, env₁₈₃	core₁₈
cHBV5	38	M	2530	14.08	45	Naive	pol₄₅₅	–
cHBV6	40	F	672	888.65	20	Naive	env₁₈₃, pol₄₅₅	pol₄₅₅
cHBV7	58	F	136	10.87	14	Naive	env₁₈₃, pol₄₅₅	env₁₈₃, pol₄₅₅
cHBV8	55	M	502	7751.10	33	Naive	env₁₈₃, pol₄₅₅	env₁₈₃, pol₄₅₅
cHBV9	53	M	41	10.45	21	Naive	core₁₈	core₁₈
cHBV10	29	F	306	652.63	14	Naive	core₁₈, env₁₈₃	core₁₈, env₁₈₃
cHBV11	77	F	367	230.79	20	Naive	core₁₈, pol₄₅₅	core₁₈, pol₄₅₅
cHBV12	25	F	34	67.48	20	Naive	core₁₈, env₁₈₃	core₁₈
cHBV13	51	M	157	90.81	20	Naive	core₁₈	core₁₈
cHBV14	55	F	87	172.98	22	Naive	core₁₈	core₁₈
cHBV15	61	M	1335	180.28	56	Naive	core₁₈	core₁₈
cHBV16	54	M	301	28.83	24	Naive	core₁₈	core₁₈
cHBV17	28	M	270	397.5	39	Naive	core₁₈	core₁₈
cHBV18	63	F	922	21.96	28	Naive	core₁₈, env₁₈₃, pol₄₅₅	core₁₈
cHBV19	34	M	345	215.07	83	Naive	env₁₈₃, pol₄₅₅	pol₄₅₅
cHBV20	33	F	1085	796.49	21	Naive	core₁₈, env₁₈₃, pol₄₅₅	core₁₈, pol₄₅₅
cHBV21	42	F	2662	233.66	16	Naive	env₁₈₃, pol₄₅₅	–
cHBV22	40	M	347	24.33	30	Naive	env₁₈₃, pol₄₅₅	–
cHBV23	49	F	nd	605.37	8	Naive	env₁₈₃, pol₄₅₅	–
cHBV24	46	M	1375	31 501	56	Naive	env₁₈₃, pol₄₅₅	–
cHBV25	36	F	44	5998.51	38	Naive	core₁₈, env₁₈₃	env₁₈₃
cHBV26	40	F	153	6667.23	24	Naive	pol₄₅₅	–
cHBV27	58	F	1842	52.80	19	Naive	pol₄₅₅	pol₄₅₅
cHBV28	47	F	657	301.06	11	Naive	env₁₈₃	env₁₈₃
cHBV29	40	F	189	nd	26	Naive	env₁₈₃	–
cHBV30	66	M	293	2409.22	19	Adefovir	core₁₈, env₁₈₃, pol₄₅₅	core₁₈, pol₄₅₅
cHBV31	32	M	146	315.73	58	Entecavir	pol₄₅₅	pol₄₅₅
cHBV32	53	F	nd	963.42	18	Entecavir	core₁₈, env₁₈₃, pol₄₅₅	pol₄₅₅
cHBV33	28	F	665	8287.79	44	Entecavir	core₁₈, env₁₈₃, pol₄₅₅	pol₄₅₅
cHBV34	47	F	50	2899.17	22	Entecavir	pol₄₅₅	pol₄₅₅
cHBV35	53	M	<10	15 623.52	54	Entecavir	core₁₈, env₁₈₃, pol₄₅₅	core₁₈, pol₄₅₅
cHBV36	53	M	<10	1394.3	31	Entecavir	core₁₈	core₁₈
cHBV37	46	F	12	2190.76	33	Entecavir	env₁₈₃, pol₄₅₅	pol₄₅₅
cHBV38	37	M	<10	3444.03	55	Entecavir	env₁₈₃, pol₄₅₅	–
cHBV39	27	F	<10	1432.94	27	Lamivudine	pol₄₅₅	–
cHBV40	51	M	<10	215.9	42	Telbivudine	env₁₈₃, pol₄₅₅	pol₄₅₅
cHBV41	31	M	60	2338.44	31	Telbivudine	env₁₈₃, pol₄₅₅	pol₄₅₅
cHBV42	48	M	33	1123.66	48	Telbivudine	env₁₈₃, pol₄₅₅	pol₄₅₅
cHBV43	42	F	<10	163.41	15	Tenofovir	core₁₈, pol₄₅₅	core₁₈, pol₄₅₅
cHBV44	30	M	<10	3049.44	28	Tenofovir	env₁₈₃, pol₄₅₅	env₁₈₃, pol₄₅₅
cHBV45	33	F	<10	3409.61	56	Tenofovir	core₁₈, env₁₈₃, pol₄₅₅	core₁₈, pol₄₅₅
cHBV46	41	M	<10	927.04	19	Tenofovir	env₁₈₃, pol₄₅₅	pol₄₅₅
cHBV47	61	F	<10	483.26	24	Tenofovir	env₁₈₃, pol₄₅₅	–
cHBV48	56	F	<10	592.12	30	Tenofovir	env₁₈₃, pol₄₅₅	env₁₈₃
cHBV49	43	F	<10	138.71	20	Tenofovir	env₁₈₃	env₁₈₃

ALT, alanine transaminase; cHBV, chronic HBV; F, female; HBsAg, HBV surface antigen; M, male; nd, not done; VL, viral load; WT, wild type.